Market Spotlight: Chemotherapy-Induced Anemia
|出版日期||內容資訊||英文 32 Pages
|關注市場分析:化療誘發性貧血 Market Spotlight: Chemotherapy-Induced Anemia|
|出版日期: 2020年02月18日||內容資訊: 英文 32 Pages||
This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The proportions of CIA and the severity of anemia vary by region, cancer type, and stage.
All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
There are only two industry-sponsored drugs in active clinical development for CIA, both of which are in Phase III. Therapies in development for CIA focus on targets such as iron and hypoxia-inducible factor-prolyl hydroxylase. These drugs are administered via the intravenous and oral routes.
The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 24.3%, and the average probability a drug advances from Phase III is 81.1%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.1 years in the overall hematology space.
There have been only two licensing and asset acquisition deals involving CIA drugs during 2015-20. The values of the deals have not been disclosed.
The distribution of clinical trials across Phase I-IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III-IV, and 39% in Phase I-II.
Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 67 trials.
Amgen leads industry sponsors with the highest number of clinical trials for CIA, followed by Johnson & Johnson.